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Abstract
Inclusion Body Myositis (IBM) is the most common acquired myopathy in older
individuals with more than two thirds of patients experiencing impaired swallowing.
There are currently no standardized exercise therapies to improve or sustain
swallowing despite good evidence for exercise therapy in limb muscles. Reduced
upper esophageal sphincter (UES) opening is a common abnormality associated with
dysphagia in IBM. This pilot study recruited IBM patients with abnormal UES function
and dysphagia into an exercise program. It was hypothesised that regular practice
using the Expiratory Muscle Strength Trainer (EMST) device would improve
hyolaryngeal movement by strengthening suprahyoid musculature and facilitate
opening of the UES thereby improving swallowing and quality of life. Overall, IBM
patients who used the EMST device demonstrated no improvement in swallowing
function. Consistent with that result, there was also no change in measures of quality
of life. However, further studies are needed to elucidate whether it has a preventative
role in the development or progression of dysphagia in IBM as there is a suggestion
that patients with a shorter duration of disease may have had some benefit. This
research provides pilot data and recommendations that will guide future studies on
exercise therapy and swallowing in this area.
Keywords: Dysphagia, Exercise therapy, Suprahyoid muscles, Pharyngeal, Upper
esophageal sphincter, Inclusion Body Myositis

1.1 Introduction
Inclusion Body Myositis (IBM) is the most common acquired myopathy in patients
over 50 years of age [1]. Dysphagia, defined as difficulty or discomfort in swallowing,
is a common symptom of the disease and occurs in 40-80% of IBM patients [2-4].
Swallowing is an essential biological function and a major contributor to quality of life;
dysphagia is linked to life-threatening medical complications such as dehydration,
malnutrition and recurrent aspiration pneumonia [5]. Any intervention that improves
swallowing function therefore has the capacity to significantly reduce morbidity and
mortality in IBM patients and improve quality of life [6]. Currently only invasive
interventions such as balloon dilation [7], cricopharyngeal myotomy [8] or injection of
botulinum toxin to the Upper Esophageal Sphincter (UES) [9-12] are known to
improve swallowing function in this population. There are no standardised exercise
devices to improve or maintain swallowing function in IBM. Langdon et al found that
dysphagia in IBM was predominantly consistent with pharyngeal and suprahyoid
muscle weakness rather than failure of UES relaxation [13]. There has been a study
investigating the effectiveness of the Mendelsohn Manoeuvre which improved
swallowing in some IBM patients [14, 15]. This manoeuvre utilises extended hold to
maintain an elevated larynx and in turn contribute to patency of UES during
swallowing.

Similar to the Expiratory Muscle Strength Trainer (EMST), the

Mendelsohn Manoeuvre targets strengthening of the suprahyoid muscles used for
hyolaryngeal movement [16]. The EMST device is however easier for patients to use.
Several studies investigating the use of exercise programmes in IBM, particularly in
relation to exercise of limb muscles are shown to be safe, feasible and significantly
improve function in patients [17-19].

The EMST is a therapeutic goods administration (TGA)-approved device currently
used in patients suffering other neurological conditions. The use of the EMST device
for dysphagia in Parkinson’s Disease has been supported with class 1 evidence and
a randomized control trial showed significant improvement in the swallowing of
Parkinson’s patients [20, 21]. Troche et al [21] suggest that their device works to
improve swallowing function through strengthening of the hyolaryngeal movement, in
turn improving the opening of the UES [21]. The device was also shown to be
effective in improving swallowing function in neuromuscular conditions such as Motor
Neuron Disease [22] and Pompe disease [23]. There have been no previous studies
investigating this device in IBM.
In keeping with the Troche et al [21] and Langdon et al [13] studies, it was
hypothesised that an exercise programme using the EMST device would strengthen
the suprahyoid muscle group and help open the UES to facilitate and improve
swallowing function and quality of life in IBM patients. The EMST device is a hand
held and inexpensive home-based therapy that if found to be effective could greatly
improve outcomes for these patients. It was the combination of these studies that led
to our hypothesis that the EMST device would improve hyolaryngeal movement in
IBM.

1.2 Aims
The aims of this pilot study were to firstly evaluate the feasibility of utilising the EMST
device to drive a directed exercise- based intervention in this patient population.
Secondly, we aimed to determine whether a 12-week exercise programme focussed
on suprahyoid swallowing muscles using the EMST device improves objective
measures of swallowing function, and quality of life for patients.

1.3 Methods
1.3.1 Participants
This pilot study was approved by the Royal Perth Hospital Human Research Ethics
Committee (RGS0000000109) and conducted in accordance with the Helsinki
Declaration of 1975. All included participants provided informed written consent. IBM
patients living in Western Australia were invited to participate in this trial through
specialised clinics at Western Australian Neurology Research Institute (WANRI) and
the Institute of Immunology and Infectious Diseases (IIID) at Murdoch University by a
consultant neurologist specialising in neuromuscular conditions (MN). All participants
completed an abridged Dysphagia Handicap Index (DHI), SF-36 Item health survey
(SF-36) [24], they underwent two instrumental swallow assessments
videofluoroscopic swallow study (VFSS) and flexible endoscopic evaluation of
swallowing (FEES). The Penetration-Aspiration Scale (PAS) and the Yale
Pharyngeal Residue Severity Rating scale (YPRSRS) were used as validated rating
tools for aspiration and residue. Participants with evidence of UES dysfunction on
VFSS were invited to undergo a 12-week exercise programme using the EMST
device.

1.3.2 Inclusion Criteria
Participants with a diagnosis of clinically-defined or pathologically-defined IBM as per
the European Neuromuscular Centre (ENMC) criteria [25] were invited to participate.
To be included in the study, participants were required have dysphagia. Dysphagia
was characterised by (but not limited to) subjective reports of difficulty swallowing
food. In addition, participants should have been able to complete baseline
questionnaires, VFSS and FEES assessments and were required to have evidence

of UES dysfunction on VFSS. Modified Barium Swallow Impairment profile (MBSImp)
rating was utilised to measure UES function identifying reduced transfer of the bolus
through the sphincter and The Yale Pharyngeal Residue Severity Rating Scale
(YPRSRS) was utilised to measure secretion or bolus residue specifically in the
piriform sinuses.
Participants also needed to provide informed consent, agree to undergo baseline and
follow up assessments and adhere to the 12-week exercise programme using the
EMST device.
Participants did not receive other standard speech therapy, swallowing treatment or
pharmacological treatment (e.g. steroids, intravenous immunoglobulin) during their
time in the study. Further to be included in the study, participants were chosen who
had not previously had botulinum toxin treatment for their dysphagia.

1.3.3 Exclusion Criteria
Participants were excluded if the dysphagia was considered due to an alternative
cause than IBM (such as an esophageal web), or if there was no evidence of UES
dysfunction on VFSS. Other exclusion criteria included: co-morbidities of neurological
origin in addition to IBM, uncontrolled asthma, COPD, emphysema or if they were
unable consent to the study, or unwilling to undertake a 12-week exercise
programme using the EMST device.

1.3.4 EMST Exercise Protocol
The EMST 150 is an expiratory muscle strength training device made of a plexiglass
tube with a one-way valve which can be calibrated between 25cmH20 and
150cmH20. A mouthpiece was used to allow better fit and more comfortable use.

Participants were instructed to hold the EMST 150 mouthpiece between their teeth,
breathe in, tighten their lips around the mouthpiece and exhale forcefully and quickly.
Airflow is blocked until the valve receives enough pressure from the exhalation to
open and produces a short and sharp whistling sound.

The pressure-threshold load on the EMST device was increased daily throughout the
first week of training by the clockwise rotation of the pressure dial. The participants
maximum threshold was when the valve failed to release with exhalation. The dial
was then rotated one quarter turn counter-clockwise to reduce the load, equating to
75% of the maximum threshold. After each week of training, this process was
repeated by the speech pathologists to determine the new threshold load.

Participants were trained by an experienced speech pathologist for 30 minutes a day
for 5 consecutive days either face to face or by telephone in the use and titration of
the EMST device similar to a prior study [21]. Participants were then given a therapy
diary to prompt them to record their daily therapy of 5 sets of 5 breaths through the
EMST device each day for 5 days per week. Following the training, participants were
seen by the speech pathologist at least once per week for the first 5 weeks to ensure
the exercises were performed correctly, and to titrate the pressures on the device.
They were then seen fortnightly thereafter either in person or by video
teleconference, (Figure 1). After 12 weeks of exercises, the swallowing assessments
including surveys Abridged Dysphagia Handicap Index (DHI), The SF-36 Health
Survey

(SF-36)[24],
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1.3.5 Videofluoroscopic Swallow Study
All participants underwent oropharyngeal VFSS swallowing examination. Participants
sat upright and their swallowing function was recorded in the lateral and AP viewing
plane with nine boluses of varying consistency and volume as per the Martin-Harris
study [26]. All VFSS assessments were rated by group consensus with experienced
speech pathologists. The severity of airway invasion was scored using the 8-point
ordinal Penetration Aspiration Scale (PAS), where 1-2 is normal, 3-5 represents
penetration, and 6-8 aspiration[27]. Swallowing was specifically assessed through all
17 components of the MBSImp as per the protocol outlined in the Martin-Harris study
[26]. Each score was determined by a distinguishable observation and group
consensus. Scales of each component ranged from 0 to 3 or points. The higher the
score, the worst the swallowing function.

1.3.6 Flexible Endoscopic Evaluation of Swallowing (FEES)
Initial transnasal FEES was performed utilising Kay Pentax EPK15000 unit including
Kaypentax camera, video and endoscope model 9213 HD, fibreoptic light source
Model LH- 150P and Olympus Medical Systems Corp ENT scope Model ENFGP2.
During the study FEES equipment was upgraded to Xion endoportable Model CFT004 with videonasendoscope EN-VC CE0482. Patients were in a sitting position and
video-recorded with a temporal resolution of 25 frames per second (FPS). Data was
collected for six boluses varying in consistency and volume in accordance with the
study protocol (thin fluids 10ml, thin fluids sequential, Level 3 moderately thick (L400)
10ml, Level 2 mildly thick (L150m) 10ml, Puree 10ml, regular diet). The YPRSRS [28]
was used to quantify the severity of the residue in the pyriform sinus and vallecula
observed during FEES. If the residue could not be viewed in any trial due to an

inability to visualise the vallecula or pyriform sinus it was scored as N/A. In addition,
severity of airway invasion was scored using the 8-point Penetration-Aspiration
(PAS) Scale.

1.3.7 Statistical Analyses
The data collected represented a sample of convenience and results were
descriptive in nature. Data was analysed through SPSS ver. 25 (SPSS, Inc.,
Chicago, IL, USA). The design of the study was single arm pre-test post-test study.
Comparison measures between VFSS, FEES and quality of life measures (DHI and
SF-36) were undertaken using paired T tests. In order to take a representative of
swallowing function, the Level 0 thin sequential, regular diet and Level 3 moderately
thick bolus (L400) conditions were selected for both VFSS and FEES. The
relationship between the PAS for VFSS and FEES was analysed through nonparametric correlation statistics. Following advice from the speech pathologist, the
FEES data and the Yale Pharyngeal Residue Severity Rating Scale were simplified
into a binary format such that scores 1, 2 and 3 of the scale (none, trace, mild) were
coded 0 and scores 4 and 5 (moderate and severe) were coded as 1 to reflect the
clinical utility of the scale. Significance was set at p ≤ 0.05 for all comparisons.

1.4 Results
1.4.1 Demographics
Fifteen participants were screened for the study. Two participants could not tolerate
the FEES assessment so were excluded from the study. One participant died during
the course of the trial following a severe stroke. A total of twelve participants
completed the pilot study and were very highly compliant with the intervention. There

were seven females (mean age =65) and five males (mean age=74 years). The
mean age of participants was 68.8 years. The mean duration of disease was 9.5
years. Table 1 depicts the demographics of the participants during this study.

1.4.2 Swallowing Function
In all IBM patients, there was no difference in the cumulative videofluroscopic
pharyngeal rating in the Level 0 thin sequential (p= 0.309) or regular bolus conditions
(p=0.139) pre-and post-training illustrated in Figure 2(a) and 3(b). There was
however a statistical difference in the pharyngeal rating in the Level 3 moderately
thick (L400) bolus condition following training illustrated Figure 2 (c) (p=0.013). FEES
analysis showed no improvement in the level of post swallow residue in the vallecular
and pyriform sinus following training with the EMST device.

1.4.3 Penetration and Aspiration Score
There was no difference in the PAS scores in both VFSS and FEES imaging
modalities pre-and post the EMST treatment. Given that PAS was measured in both
the VFSS and FEES imaging modalities, the strength of association was measured
between the two scores from each modality in two different contexts using nonparametric correlation statistics. The relationship between the PAS scores was poor
for: level 0 thin bolus condition pre (r= 0.098) and post training (r=0.188) and level 3
moderately thick condition pre (r=0.101) and post training (r=0.661).

1.4.4 EMST Device in early IBM
Four participants were classified as having early IBM (duration of disease <5 years).
There was no difference in cumulative pharyngeal videofluroscopic swallow study
measures (level 0 thin, p=0.18; regular, p=0.09; level 3 moderately thick, p=0.06) or

quality of life in all four participants. Two participants with a more recent diagnosis
(had significant reduction of residue in the vallecula after the use of the EMST
training device (ID 2, p=0.001 & ID 9, p=0.01). There was also significant reduction of
residue in the piriform sinus in one of the participants (ID 9) with recently diagnosed
IBM (p=0.04). Unfortunately, the data obtained from the other two participants with
early IBM could not be analysed to verify a trend due to inability to visualise the
vallecula or pyriform sinus in the FEES assessment either pre-or post the use of the
device in these participants (ID 8 and 12).

1.4.5 Quality of life
There was no change in either the abridged Dysphagia Handicap Index or the SF-36
quality of life measures after EMST exercise regime as illustrated in Tables 2 and 3.
However, the results of the abridged Dysphagia Handicap Index illustrate that
participants scored higher and therefore generally report more distress with the
functional and emotional aspects of their dysphagia compared to the physical (Table
2). Similar to this trend, where 100 denotes the highest value of each subset of the
SF-36 scoring system, Table 3 shows that participants scored higher in the
Emotional Well-being, Pain and Social Functioning questions compared to the
Physical Functioning questions.

1.5 Discussion
This exploratory study was designed to establish whether the EMST device would
improve suprahyoid strength and in turn hyolaryngeal complex movement and
therefore its’ associated role in the swallowing of participants diagnosed with IBM.
The overall results of this pilot study did not support the proposed prediction that 12

weeks of EMST training will result in improved swallowing function and better quality
of life for participants. However, the severity of dysphagia and duration of disease
were not taken into consideration, as there was a trend towards improvement in
patients with a shorter disease duration. This study was inadequately powered to
draw firm conclusions regarding disease duration and utility of the EMST
intervention. In addition, this was a short-term pilot study designed as a short-term
intervention to detect a positive difference, which may inform future longer
prospective studies where it may play a more significant role in prevention of
dysphagia.
This study contributes to the literature regarding the lack of correlation between two
different instrumental swallowing modalities (VFSS and FEES). Prior studies have
also reported a similar discrepancy between the measurements of PAS in VFSS and
FEES [29, 30]. The accurate assessment of penetration and aspiration is important
and the lack of reliability between the two different imaging modalities is concerning.
This discrepancy between the measurement of penetration or aspiration between
FEES and VFSS was also found in this study in IBM patients. This has potential
critical implications for aspiration and penetration risk in IBM patients. The VFSS
results are subjected to more stringent measurements. Similarly, factors affecting
the internal reliability of the FEES include the fact that some patients find it difficult to
tolerate.
In this pilot study, there was improvement of swallowing function noted in the VFSS
of the level 3 moderately thick bolus condition (L400) compared with thin and regular
fluid consistencies after EMST training. This was not reproducible in the FEES
assessment. The literature shows that 82% of people with dysphagia associated with
IBM have most difficulty swallowing solids rather than liquids [15, 31, 32]. Cook et. al,

and Dantas et. al, demonstrated that with a larger bolus, pharyngeal function began
earlier so as to prepare the deglutitive chamber for a larger and subsequently higher
velocity bolus [33, 34]. Specifically, according to the Dantas et al study the major
effect of increased bolus volume was earlier onset of anterior tongue base
movement, superior palatal movement, anterior laryngeal movement and UES
opening [34]. Earlier UES opening was documented to be associated with an
increased duration of sphincter opening [33].

It is plausible, therefore, that the

difference in the large bolus condition may have been functional improvement due to
the EMST device. However, as this result was not evident in the FEES assessment,
and whether the significant result of the VFSS moderately thick bolus condition is
indicative of a true result or measurement error needs to be further investigated.
Perhaps, the effectiveness of the EMST device would have been better assessed
through manometry which has the potential to evaluate pressures generated by the
pharyngeal muscles pre-and post the device, however this is not a standard test in
our clinic thus not selected for this pilot. In addition, the use of different outcome
measures that are more specific for the physiologic measures of the swallow
mechanism such as the SWAL-QoL, SSQ or Anderson may have been a better
measure for quality of life than the DHI and SF-36 [35].
This pilot study had many limitations. Firstly, and importantly for an exercise
intervention, we did not control for disease duration or severity of dysphagia which
would have limited sample size at this single centre. We would anticipate that this
intervention would be more effective in earlier disease stages than when the muscle
involvement is already too severe to respond to an exercise intervention. While there
was no improvement observed on VFSS assessment, our results suggest that there
was improvement in swallowing in the FEES assessment in this early group where it

could be measured however given this trend was observed in only two patients
whether it is representative of a true result warrants further investigation. The level of
statistical significance obtained in the two patients is however very large suggesting
that patients in earlier disease stages are most likely to benefit.
There are several issues that future studies investigating dysphagia in IBM could
consider. Firstly, future studies should attempt to control IBM disease duration and
dysphagia severity. The segregation of early verses late-stage IBM may reveal the
role of EMST as a preventative intervention for dysphagia rather than restorative
once the muscle weakness is already too severe. A correlation analysis between
swallowing function and skeletal muscle weakness or cN1A may be fruitful. Secondly
the variable outcomes detected between VFSS and FEES leave open the best way
to diagnose and monitor dysphagia in IBM patients. Perhaps manometry or MRI may
be more specific and more sensitive [36]. Although currently they are not readily
available in a clinical environment. Lastly, the small cohort size and the lack of a
placebo arm serves as a limitation to this study albeit difficult to facilitate.
Given these limitations, this pilot study does not exclude exercise therapy has an
effect on maintaining or perhaps even improving swallowing function in IBM. The
effect of exercise therapies in swallowing should be investigated in IBM patients
through different modalities.

1.6 Conclusion
This pilot study investigated the use of the EMST device in twelve participants with
dysphagia secondary to IBM. This is the first reported study that investigated the use
of an exercise device to aid swallowing function in IBM patients and showed it was
feasible for IBM patients. This pilot study provides some useful lessons for future

studies on exercise therapies and dysphagia in IBM. A study on a larger, less severe
cohort over a longer period and using different measures is warranted to clarify the
role if any, of the EMST device in IBM patients.
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Figure 1 EMST study timeline

Figure 2a and 2b Cumulative pharyngeal MBSImp score pre-and post the EMST
device in the Level 0 thin and regular sequential bolus condition

Figure 2c Cumulative pharyngeal MBSImp score pre-and post the EMST device in
the Level 3 Moderately thick bolus condition (L400)

Table 1 Demographics of the participants recruited in this pilot study
Participant Sex Age (years)
ID

Duration of disease
(years)

1 F

70

17

2 F

59

3

3 M

76

13

4 M

77

18

5 F

69

6

6 M

77

10

7 F

72

12

8 F

56

1

9 M

67

4

10 F

61

10

11 F

68

16

12 M

73

4

Table 2 The abridged Dysphagia Handicap Index results
Pre EMST

Post EMST

Mean Difference

p value

9.83

0.25

0.760

Functional 18.25

19.17

-0.917

0.511

Emotional 13.42

13.82

-0.415

0.724

Physical 10.08

Table 3 The SF-36 Health Survey results
Pre EMST

Post EMST

Mean Difference p value

Physical Functioning

24.17

24.92

-0.75

0.804

Emotional Well-being

75.33

74

1.33

0.762

66.67

-0.21

0.970

62.5

0

1.0

Pain 66.46
Social Functioning 62.5

